129 related articles for article (PubMed ID: 38738450)
1. Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.
Gantenberg JR; van Aalst R; Bhuma MR; Limone B; Diakun D; Smith DM; Nelson CB; Bengtson AM; Chaves SS; La Via WV; Rizzo C; Savitz DA; Zullo AR
J Pediatric Infect Dis Soc; 2024 Jun; 13(6):317-327. PubMed ID: 38738450
[TBL] [Abstract][Full Text] [Related]
2. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
Gantenberg JR; van Aalst R; Zimmerman N; Limone B; Chaves SS; La Via WV; Nelson CB; Rizzo C; Savitz DA; Zullo AR
J Infect Dis; 2022 Aug; 226(Suppl 2):S164-S174. PubMed ID: 35968869
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
4. The clinical impact of multiple prevention strategies for respiratory syncytial virus infections in infants and high-risk toddlers in the United States.
Ektare V; Lang J; Choi Y; Finelli L
Vaccine; 2022 Oct; 40(42):6064-6073. PubMed ID: 36096968
[TBL] [Abstract][Full Text] [Related]
5. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
Straňák Z; Saliba E; Kosma P; Posfay-Barbe K; Yunis K; Farstad T; Unnebrink K; van Wyk J; Wegzyn C; Notario G; Kalus S; Campbell FJ
PLoS One; 2016; 11(6):e0157446. PubMed ID: 27310438
[TBL] [Abstract][Full Text] [Related]
6. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
[TBL] [Abstract][Full Text] [Related]
9. Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
Nelson CB; Brady BL; Richards M; Lew CR; Via W; Greenberg M; Rizzo C
Vaccine; 2023 Sep; 41(40):5820-5824. PubMed ID: 37586957
[TBL] [Abstract][Full Text] [Related]
10. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
[TBL] [Abstract][Full Text] [Related]
11. Model correction of diagnostic coding-based RSV incidence for children 0-4 years in the US.
Nduaguba SO; Tran PT; Winterstein AG
BMC Infect Dis; 2024 Jun; 24(1):617. PubMed ID: 38907351
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study.
Ozkan H; Celebi S; Koksal N; Hacımustafaoğlu M; Koc E; Tezer H; Cetinkaya M; Cebeci B; Erdeve O; Ozdemir H;
Am J Perinatol; 2021 Dec; 38(14):1540-1546. PubMed ID: 32659789
[TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
[TBL] [Abstract][Full Text] [Related]
15. The effect of birth month on the risk of respiratory syncytial virus hospitalization in the first year of life in the United States.
Lloyd PC; May L; Hoffman D; Riegelman R; Simonsen L
Pediatr Infect Dis J; 2014 Jun; 33(6):e135-40. PubMed ID: 24445838
[TBL] [Abstract][Full Text] [Related]
16. An outbreak of RSV infections in a neonatology clinic during the RSV-season.
Vakrilova L; Nikolova SH; Slavov S; Radulova P; Slancheva B
BMC Pediatr; 2021 Dec; 21(1):567. PubMed ID: 34895173
[TBL] [Abstract][Full Text] [Related]
17. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
18. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
[TBL] [Abstract][Full Text] [Related]
19. Defining RSV epidemic season in southwest China and assessing the relationship between birth month and RSV infection: A 10-year retrospective study from June 2009 to May 2019.
Li T; Fang H; Liu X; Deng Y; Zang N; Xie J; Xie X; Luo Z; Luo J; Liu Y; Fu Z; Ren L; Liu E
J Med Virol; 2023 Jul; 95(7):e28928. PubMed ID: 37455559
[TBL] [Abstract][Full Text] [Related]
20. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
